NCT04789980Completed
Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
A Multi-center, Prospective, Observational Study to Evaluate Palliative Chemotherapy Patterns and Prognosis in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 12 Sept 2025
Brief summary (registry, in English)
The study objectives are to find out: 1) palliative chemotherapy patterns and prognosis in patients with locally advanced or metastatic pancreatic cancer in Korea's real clinical settings, and 2) reasons adopted by clinicians in choosing therapeutic drugs.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 799 (actual)
- First submitted
- 2 Mar 2021
- Start date
- 29 Jan 2021
- Primary completion date
- 24 Jun 2025
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Diseases
- Pancreatic cancer
- NCT number
- NCT04789980
What you commit to
- Study type: Observational
- Participants enrolled: 799
- From 29 Jan 2021 to the primary completion date, 24 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are currently or have a history of receiving palliative chemotherapy.
- Patients who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the study period. However, patients participating in a non-interventional observational study or registry study can be enrolled.
Other illness
- Patients who are diagnosed with any other primary cancer that may influence pancreatic cancer treatment or prognosis.
Other
- Female patients who are pregnant, have childbearing potential or are breastfeeding.
- Other patients who are judged by the investigator to be ineligible to participate in the study.
Who the study is looking for
- Patients are briefed about the study objectives and methodologies, and express their consent by signing a written agreement for the use of their personal information.
- Male and female adults who are ≥ 19 years old at the time of enrollment.
- Locally advanced or metastatic pancreatic cancer patients whose diagnosis was confirmed histologically or cytologically.
- Patients who plan to receive palliative chemotherapy (e.g., FOLFIRINOX, Gemcitabine-based therapy, etc.)
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Catholic University of Korea, Seoul ST. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.